Zydus Cadila gets USFDA nod to market its transdermal product

The company has received approval from the United States Food and Drug Administration to market its Rivastigmine transdermal system 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs.

from Moneycontrol Business News https://ift.tt/2HiIYdJ